Abstract:[Objective] The aim of our study is to express Antrodia camphorata immunomodulatory protein (ACA) in Escherichia coli efficiently.[Methods] We synthesized ACA gene with E. coli codon bias using DNAWorks 3.2.4 program to design and optimize primers. Then, we sequenced the PCR products, inserted the correct gene into expression vector pET-32a and pGEX-4t-2, transformed them into E. coli and named them pET-32a-ACA/BL21 and pGEX-4t-2-ACA/BL21 respectively after sequencing. We investigated the effects of codon bias, vectors, mediums and the induction conditions on the expression of recombinant ACA (rACA), and further optimized the protein expression using response surface methodology (RSM) subsequently. To evaluate the bioactivity of rACA, we determined the proliferation of RAW264.7 cells, analyzed the phagocytosis of macrophages, observed the cell morphology, detected the secretion of cytokine such as nitric oxide (NO), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) after treated RAW264.7 cells with purified rACA. [Results] pET-32a-ACA/BL21 was more suitable for the expression of ACA. The rACA was expressed mainly in soluble form with a yield of 187.122 μg/mL, when the pET-32a-ACA/BL21 was cultured in optimized SOB medium (8.92 g/L yeast extract) and induced with 0.42 mmol/L IPTG at 25 ℃ for 7 h. This was the highest expression report for fungal immunomodulatory protein in E. coli so far. Moreover, the purified rACA promoted the proliferation of RAW264.7, enhanced the phagocytosis activity, changed the cell morphology as well as induced NO, TNF-a and IL-1β production within murine macrophages. [Conclusion] The highly soluble expression, and the very similar biological activities to native ACA make it a good candidate of native ACA for potential application as a food supplement or immunomodulatory agent in pharmaceuticals and even medical studies.